# Cyclerion Therapeutics, Inc. (CYCN) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_486723553a787ad1048d · retrieved 2026-08-12T07:23:57.754Z

## Overview
Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases; it is acquiring Korsana Biosciences, which has a pipeline including KRSA-028 and the THETA platform for neurodegeneration.

Cyclerion Therapeutics, Inc. announced a proposed merger with Korsana Biosciences, Inc. pursuant to an Agreement and Plan of Merger and Reorganization dated April 1, 2026. Under the transaction structure, Cyclerion's wholly-owned subsidiary Cariboos Merger Sub Corp. will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion. Immediately following, Korsana will merge with and into Cyclerion's second merger subsidiary, Cariboos Merger Sub II, LLC. The combined company is expected to be listed on Nasdaq under a new name and ticker symbol following completion of the merger. Korsana brings a pipeline of potential best-in-class therapies for neurodegenerative diseases, including the lead candidate KRSA-028.

## Terms
- Counterparty: Korsana Biosciences, Inc.

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 425 (0001193125-26-338459): 425 - Cyclerion Therapeutics, Inc. — *Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases; it is acquiring Korsana Biosciences, which has a pipeline of potential best-in-class therapies including KRSA-028 and the THETA platform.* Cyclerion Therapeutics, Inc. has entered into an Agreement and Plan of Merger and Reorganization dated April 1, 2026, with Korsana Biosciences, Inc. Under the agreement, Cyclerion's wholly-owned subsidiary Cariboos Merger Sub Corp. will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion. Immediately following, Korsana will merge with and into Cyclerion's second merger subsidiary, Cariboos Merger Sub II, LLC. The transaction is subject to customary closing conditions and shareholder approval. The combined company is expected to advance Korsana's KRSA-028 program and leverage the THETA platform for neurodegenerative disease therapies.
  https://www.sec.gov/Archives/edgar/data/1755237/0001193125-26-338459.txt
- 2026-08-10 · 425 (0001193125-26-342584): 425 - Cyclerion Therapeutics, Inc. — *Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases; it is acquiring Korsana Biosciences, which has a pipeline including KRSA-028 and the THETA platform for neurodegeneration.* Cyclerion Therapeutics, Inc. announced a proposed merger with Korsana Biosciences, Inc. pursuant to an Agreement and Plan of Merger and Reorganization dated April 1, 2026. Under the transaction structure, Cyclerion's wholly-owned subsidiary Cariboos Merger Sub Corp. will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion. Immediately following, Korsana will merge with and into Cyclerion's second merger subsidiary, Cariboos Merger Sub II, LLC. The combined company is expected to be listed on Nasdaq under a new name and ticker symbol following completion of the merger. Korsana brings a pipeline of potential best-in-class therapies for neurodegenerative diseases, including the lead candidate KRSA-028.
  https://www.sec.gov/Archives/edgar/data/1755237/0001193125-26-342584.txt

## Citations
- 0001193125-26-338459 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526338459
- 0001193125-26-342584 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526342584